XML 19 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Revenue:      
Testing revenue $ 29,680 $ 27,881 $ 25,842
Product revenue 10,715 0 0
Collaboration and license revenue 236 263 1,464
Total revenue 40,631 28,144 27,306
Operating expenses:      
Cost of testing 10,882 10,273 8,541
Cost of product 10,240 0 0
Research and development 12,385 9,333 3,846
Sales and marketing 11,166 8,349 6,472
General and administrative 20,725 12,247 8,436
Goodwill impairment 13,021 0 0
Change in estimated fair value of contingent consideration (456) (126) (1,239)
Total operating expenses 77,963 40,076 26,056
(Loss) income from operations (37,332) (11,932) 1,250
Interest expense, net (1,860) (1,587) (2,116)
Other (expense) income, net (1,920) (188) (78)
Change in estimated fair value of common stock warrant and derivative liabilities (250) 0 225
Loss before income taxes (41,362) (13,707) (719)
Income tax benefit 1,606 0 1,500
Net (loss) income (39,756) (13,707) 781
Net (loss) income attributable to noncontrolling interest (287) 0 0
Net (loss) income attributable to CareDx, Inc. $ (39,469) $ (13,707) $ 781
Net (loss) income per share attributable to CareDx, Inc. (Note 3):      
Basic $ (2.39) $ (1.16) $ 0.13
Diluted $ (2.39) $ (1.16) $ 0.10
Weighted average shares used to compute net (loss) income per share attributable to CareDx, Inc.:      
Basic 16,496,911 11,860,885 5,815,928
Diluted 16,496,911 11,860,885 9,283,001